

# Stanley R Riddell

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4640421/stanley-r-riddell-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

85  
papers

15,295  
citations

50  
h-index

88  
g-index

88  
ext. papers

18,348  
ext. citations

11.5  
avg, IF

6.53  
L-index

#	Paper	IF	Citations
85	Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. <i>New England Journal of Medicine</i> , <b>1995</b> , 333, 1038-44	59.2	1563
84	CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. <i>Journal of Clinical Investigation</i> , <b>2016</b> , 126, 2123-38	15.9	1143
83	Costimulation of CD8alpha T cells by NKG2D via engagement by MIC induced on virus-infected cells. <i>Nature Immunology</i> , <b>2001</b> , 2, 255-60	19.1	791
82	Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. <i>Cancer Discovery</i> , <b>2017</b> , 7, 1404-1419	24.4	649
81	Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. <i>Journal of Clinical Investigation</i> , <b>2008</b> , 118, 294-305	15.9	633
80	Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. <i>Science Translational Medicine</i> , <b>2016</b> , 8, 355ra116	17.5	613
79	Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. <i>Blood</i> , <b>2017</b> , 129, 3322-3331	2.2	582
78	Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. <i>Blood</i> , <b>2017</b> , 130, 2295-2306	2.2	522
77	A critical role for tapasin in the assembly and function of multimeric MHC class I-TAP complexes. <i>Science</i> , <b>1997</b> , 277, 1306-9	33.3	436
76	Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. <i>Blood</i> , <b>2016</b> , 127, 2406-10	2.2	436
75	Therapeutic T cell engineering. <i>Nature</i> , <b>2017</b> , 545, 423-431	50.4	420
74	Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3010-3020	2.2	396
73	CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. <i>Blood</i> , <b>2012</b> , 119, 3940-50	2.2	396
72	A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. <i>Blood</i> , <b>2011</b> , 118, 1255-63	2.2	382
71	Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. <i>Journal of Experimental Medicine</i> , <b>2000</b> , 192, 1637-44	16.6	374
70	Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 3153-64	12.9	330
69	The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. <i>Journal of Immunological Methods</i> , <b>1990</b> , 128, 189-201	2.5	298

68	The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. <i>Cancer Immunology Research</i> , <b>2015</b> , 3, 125-35	12.5	294
67	Adoptive cellular therapy: a race to the finish line. <i>Science Translational Medicine</i> , <b>2015</b> , 7, 280ps7	17.5	252
66	Engineering CAR-T cells: Design concepts. <i>Trends in Immunology</i> , <b>2015</b> , 36, 494-502	14.4	247
65	Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. <i>Blood</i> , <b>2018</b> , 131, 121-130	2.2	225
64	Principles for adoptive T cell therapy of human viral diseases. <i>Annual Review of Immunology</i> , <b>1995</b> , 13, 545-86	34.7	214
63	Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8(+) central memory T cells. <i>Immunity</i> , <b>2014</b> , 41, 116-26	32.3	203
62	The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. <i>Blood</i> , <b>2010</b> , 116, 4532-41	2.2	200
61	Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. <i>Science Signaling</i> , <b>2018</b> , 11,	8.8	192
60	Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts. <i>Journal of Clinical Investigation</i> , <b>2015</b> , 125, 2677-89	15.9	191
59	Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. <i>Blood</i> , <b>2016</b> , 127, 2980-90	2.2	191
58	Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. <i>Blood</i> , <b>2010</b> , 115, 3869-78	2.2	188
57	Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. <i>Journal of Clinical Investigation</i> , <b>2016</b> , 126, 4262-4272	15.9	162
56	Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. <i>Blood</i> , <b>2019</b> , 133, 1652-1663	2.2	158
55	Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells. <i>Blood</i> , <b>2012</b> , 119, 72-82	2.2	152
54	Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates. <i>Cancer Discovery</i> , <b>2018</b> , 8, 750-763	24.4	136
53	Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma. <i>PLoS ONE</i> , <b>2013</b> , 8, e82742	3.7	132
52	Role of memory T cell subsets for adoptive immunotherapy. <i>Seminars in Immunology</i> , <b>2016</b> , 28, 28-34	10.7	129
51	The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. <i>Blood</i> , <b>2019</b> , 133, 1876-1887	2.2	126

50	Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting. <i>Cancer Cell</i> , <b>2019</b> , 35, 489-503.e8	24.3	123
49	Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. <i>Blood</i> , <b>2019</b> , 134, 1585-1597	2.2	120
48	Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. <i>Blood</i> , <b>2020</b> , 135, 1650-1660	2.2	115
47	Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells. <i>Cancer Immunology Research</i> , <b>2015</b> , 3, 206-16	12.5	112
46	Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy. <i>Journal of Immunology</i> , <b>2018</b> , 200, 459-468	5.3	109
45	Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. <i>Immunological Reviews</i> , <b>2014</b> , 257, 127-44	11.3	109
44	Chimeric antigen receptor-modified T cells: CD19 and the road beyond. <i>Blood</i> , <b>2018</b> , 131, 2621-2629	2.2	96
43	High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. <i>Blood</i> , <b>2019</b> , 134, 636-640	2.2	89
42	Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 3061-3071	12.9	89
41	Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells. <i>Blood</i> , <b>2010</b> , 115, 4923-33	2.2	85
40	Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment. <i>PLoS ONE</i> , <b>2014</b> , 9, e96565	3.7	81
39	Engineering human peripheral blood stem cell grafts that are depleted of naive T cells and retain functional pathogen-specific memory T cells. <i>Biology of Blood and Marrow Transplantation</i> , <b>2014</b> , 20, 705-16	4.7	75
38	TCR-ligand koff rate correlates with the protective capacity of antigen-specific CD8+ T cells for adoptive transfer. <i>Science Translational Medicine</i> , <b>2013</b> , 5, 192ra87	17.5	69
37	Fully Human Bcma Targeted Chimeric Antigen Receptor T Cells Administered in a Defined Composition Demonstrate Potency at Low Doses in Advanced Stage High Risk Multiple Myeloma. <i>Blood</i> , <b>2018</b> , 132, 1011-1011	2.2	62
36	Novel serial positive enrichment technology enables clinical multiparameter cell sorting. <i>PLoS ONE</i> , <b>2012</b> , 7, e35798	3.7	50
35	Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade. <i>Cancer Cell</i> , <b>2021</b> , 39, 193-208.e10	24.3	50
34	Designed protein logic to target cells with precise combinations of surface antigens. <i>Science</i> , <b>2020</b> , 369, 1637-1643	33.3	48
33	Graft-Derived Reconstitution of Mucosal-Associated Invariant T Cells after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 242-251	4.7	46

32	Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells <b>2014</b> , 2, 36		45
31	Inclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy. <i>Nature Biotechnology</i> , <b>2016</b> , 34, 430-4	44.5	42
30	Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. <i>Blood</i> , <b>2021</b> , 137, 323-335	2.2	39
29	Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Fludarabine and Cyclophosphamide Lymphodepletion Improves In Vivo Expansion and Persistence of CAR-T Cells and Clinical Outcomes. <i>Blood</i> , <b>2015</b> , 126, 184-184	2.2	36
28	T-cell therapy of leukemia. <i>Cancer Control</i> , <b>2002</b> , 9, 114-22	2.2	30
27	Addition of Fludarabine to Cyclophosphamide Lymphodepletion Improves In Vivo Expansion of CD19 Chimeric Antigen Receptor-Modified T Cells and Clinical Outcome in Adults with B Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2015</b> , 126, 3773-3773	2.2	29
26	Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy. <i>Blood Advances</i> , <b>2019</b> , 3, 3590-3601	7.8	27
25	Cytomegalovirus Exposure in the Elderly Does Not Reduce CD8 T Cell Repertoire Diversity. <i>Journal of Immunology</i> , <b>2019</b> , 202, 476-483	5.3	27
24	Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 7506-7516	12.9	23
23	Finding a place for tumor-specific T cells in targeted cancer therapy. <i>Journal of Experimental Medicine</i> , <b>2004</b> , 200, 1533-7	16.6	22
22	Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab. <i>Cancer Immunology Research</i> , <b>2016</b> , 4, 509-19	12.5	16
21	Human HLA-A*02:01/CHM1+ allo-restricted T cell receptor transgenic CD8+ T cells specifically inhibit Ewing sarcoma growth in vitro and in vivo. <i>Oncotarget</i> , <b>2016</b> , 7, 43267-43280	3.3	12
20	Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function. <i>Science Signaling</i> , <b>2021</b> , 14,	8.8	11
19	CD19 CAR-T Cells Are Highly Effective in Ibrutinib-Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2016</b> , 128, 56-56	2.2	10
18	Human Minor Histocompatibility Antigen-Specific CD8+ T Cells Are Found Predominantly in the CD45RA+ CD62L+ Nai ve T Cell Subset.. <i>Blood</i> , <b>2005</b> , 106, 578-578	2.2	6
17	Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2101755	2.2	4
16	High IL-15 Serum Concentrations Are Associated with Response to CD19 CAR T-Cell Therapy and Robust In Vivo CAR T-Cell Kinetics. <i>Blood</i> , <b>2020</b> , 136, 37-38	2.2	4
15	A BiTE from cancer's intracellular menu. <i>Nature Biotechnology</i> , <b>2015</b> , 33, 1040-1	44.5	3

14	The Non-Signaling Extracellular Spacer Domain of CD19-Specific Chimeric Antigen Receptors Is Decisive for in Vivo Anti-Tumor Activity. <i>Blood</i> , <b>2012</b> , 120, 951-951	2.2	3
13	Metabolic regulation by PD-1 signaling promotes long-lived quiescent CD8 T cell memory in mice. <i>Science Translational Medicine</i> , <b>2021</b> , 13, eaba6006	17.5	3
12	Dual Targeting with CAR T Cells to Limit Antigen Escape in Multiple Myeloma. <i>Blood Cancer Discovery</i> , <b>2020</b> , 1, 130-133	7	3
11	Tumor-infiltrating lymphocytes make inroads in non-small-cell lung cancer. <i>Nature Medicine</i> , <b>2021</b> , 27, 1339-1341	50.5	2
10	Viral Genome Scan for Analysis of CMV-Specific CD8+ T Cells in Normal and Immunocompromised Individuals.. <i>Blood</i> , <b>2007</b> , 110, 1068-1068	2.2	1
9	Synthetic receptors for logic gated T cell recognition and function. <i>Current Opinion in Immunology</i> , <b>2021</b> , 74, 9-17	7.8	1
8	Adoptive Cellular Therapy for Follicular Lymphoma Using Genetically-Modified Autologous CD20-Specific T Cells.. <i>Blood</i> , <b>2007</b> , 110, 499-499	2.2	0
7	Tinkering in the garage - tuning CARs for safety. <i>Nature Reviews Clinical Oncology</i> , <b>2019</b> , 16, 530-532	19.4	
6	Impact of Homozygous Deletion of UGT2B17 on Outcome of Allogeneic BMT.. <i>Blood</i> , <b>2004</b> , 104, 1837-1837		
5	IL15, but Not IL2, Supports Long-Term Survival and Function of Human and Macaque Antigen-Specific CD8+ T Cell Clones.. <i>Blood</i> , <b>2004</b> , 104, 3237-3237	2.2	
4	Increased Risk for Treatment-Related Mortality of Bone Marrow Transplantation in GSTM1-Positive Recipients.. <i>Blood</i> , <b>2005</b> , 106, 1756-1756	2.2	
3	Development of Chronic Lymphocytic Leukemia (CLL) Reactive Cytotoxic T Lymphocytes after Non-Myeloablative Hematopoietic Stem Cell Transplant Correlates with Anti-Leukemia Response.. <i>Blood</i> , <b>2006</b> , 108, 413-413	2.2	
2	Cytomegalovirus-Specific T Cells Are Elicited Early After Umbilical Cord Blood Transplant but Fail to Expand In Vivo and Control Virus Replication. <i>Blood</i> , <b>2011</b> , 118, 1974-1974	2.2	
1	Synthetic HLA-independent T cell receptors for cancer immunotherapy.. <i>Cancer Cell</i> , <b>2022</b> , 40, 359-361	24.3	